RSA Viewpoints
IQ might get you hired but EQ will get you promoted
The rise of EQ is interesting because it goes hand in hand with technological and sociological evolution. 20-30 years ago, leaders were sought (predominately)...
Who can put a price on cell and gene therapy?
Insights from the Endpoints UK Biotech Summit October 2019 Fifteen years ago, Health Economics Outcomes Research (HEOR) was the pharma industry’s new kid on...
Unleashing The Power of Interims
Businesses are dynamic; they grow, contract, fail and succeed. Research has firmly established that this process is vital to productivity and sustained growth in...
RSA Talent Talks debut Podcast
We’re seeing some of the most exciting new therapeutics emerge from the Cell & Gene Therapy Sector, it’s happening quickly and delivering meaningful results...
The Human Factor in MedTech
The medtech industry is growing rapidly, with projected compound annual growth rates of 5.6% worldwide from 2017, reaching $595 billion by 2024. This raises the...
Anyone for T?
The increasing demand for highly specialised skill sets in drug development Do employers prefer specialists or generalists? While many would answer ‘it depends’, the...
What’s the Outlook for MedTech in 2019? Key Challenges and Opportunities
This is a complex time for the MedTech industry, with many challenges and opportunities ahead. Innovative technologies are constantly evolving, and we’re seeing increasing...
Making the leap into self-employment? Don’t be an interim lemming
Deciding to work for yourself is a big leap of faith and varies considerably from the well-trodden path of employment. So, it pays to...
JPM 2019 |The fundamentals remain strong despite the doubters
I’ve taken longer than usual to write my JPM blog this year. It was a week when there was such a division of opinion...
RSA Viewpoint | 2019 Outlook
Smart thinking can overcome talent shortages in 2019 As we leave 2018, we’re living through fast growing surge of change, to which the Life...
RSA Viewpoint | Why we should stop talking about Diversity & Inclusion Initiatives
We know the life sciences sector desperately needs diversity across the board. The industry is facing a demographic time bomb: many of the current...
Launching your first medical product in Europe? How not to fail at the first step
So, you have your first product close to launch or are even on the market in the U.S. You’re planning to take it to...
AMRC | HR Benchmarking Report
In May 2018, the Association of Medical Research Charities (AMRC) circulated a survey of 50 questions to member charity CEOs and formal representatives. The...
Brexit’s Uncertainty Principle
While the minutiae of the possible upcoming permutations for drug supply depending on various Brexit outcomes have been written about elsewhere, less thought has been...
Bringing fresh talent into the Alzheimer’s space
It’s more than 15 years since the pharmaceutical industry succeeded in launching a new drug to treat Alzheimer’s disease. Since then, over 99% of...
Pharmafile | The Value of Measuring Board Performance
Nick Stephens of The RSA Group discusses the importance of stopping to quantify the effectiveness of board members within life sciences, and offers guidance...
Employers Using Social Media More and More to Screen Candidates
According to a new CareerBuilder survey, 70 percent of employers use social media to screen candidates before hiring, up from 60 percent just two...